{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:32:22Z","timestamp":1781620342381,"version":"3.54.5"},"reference-count":38,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970757"],"award-info":[{"award-number":["81970757"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270938"],"award-info":[{"award-number":["82270938"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-006"],"award-info":[{"award-number":["2022-PUMCH-D-006"]}]},{"name":"Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2023-PT320-10"],"award-info":[{"award-number":["2023-PT320-10"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0532204"],"award-info":[{"award-number":["2024ZD0532204"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-002"],"award-info":[{"award-number":["2021-I2M-1-002"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFC2501700"],"award-info":[{"award-number":["2021YFC2501700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Osteoporosis (OP) is a systemic skeletal disorder that increases fragility and susceptibility to fractures. Despite the availability of teriparatide for the treatment of patients with acute fractures with better efficacy, its long-term daily injection and high cost limit its broader use among a wider patient population, especially for those living in low- and middle-income countries. This study aims to evaluate the efficacy of a novel sequential treatment with teriparatide daily for 6 months followed by denosumab every 6 months for another 18 months, in comparison with denosumab monotherapy every 6 months for 24 months, in reducing the risk of fractures in patients with newly diagnosed osteoporotic fractures. The study will also explore the possible difference between two sequential treatments (shifting to denosumab treatment at 6 or 12 months) in their effect on increasing bone mineral density (BMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is designed as a multicentre, open-label, randomised controlled trial among 2478 patients with newly diagnosed osteoporotic fractures from 58 hospitals across China. Participants will be randomly assigned in a 10:10:1 ratio to three treatment groups: 24 months of denosumab monotherapy, early sequential treatment (teriparatide for 6 months followed by denosumab for 18 months) and late sequential treatment (teriparatide for 12 months followed by denosumab for 12 months). The primary outcome is the incidence of vertebral fractures over 24 months of treatment. Secondary outcomes include changes in BMD at the lumbar spine, total hip and femoral neck, changes in bone turnover markers (\u03b2-carboxy-terminal telopeptide of type 1 collagen and procollagen type 1 N-terminal propeptide), treatment adherence and cost-effectiveness. Follow-up assessments are scheduled at 3, 6, 9, 12, 18 and 24 months post-randomisation for primary and secondary outcomes, and biannually afterwards for the primary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol has been registered on ClinicalTrials.gov and has received ethical approval from the Peking Union Medical College Hospital Medical Science Research Ethics Committee (1-22PJ939). The findings will be disseminated through peer-reviewed scientific journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05866029\">NCT05866029<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-111364","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:15:29Z","timestamp":1772115329000},"page":"e111364","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of sequential denosumab after teriparatide for 6 months compared with denosumab monotherapy in reducing risk of osteoporotic fractures in patients with new fractures: a multicentre randomised controlled trial (STAND study) protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05866029","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yue","family":"Chi","sequence":"first","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Peking University Clinical Research Institute, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yuan","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Pang","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Cui","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Jiajue","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8037","authenticated-orcid":false,"given":"Huijuan","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University Clinical Research Institute, Peking University Health Science Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-3535","authenticated-orcid":false,"given":"Gaoqiang","family":"Xie","sequence":"additional","affiliation":[{"name":"Data Management, Peking University Clinical Research Institute, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4451-1932","authenticated-orcid":false,"given":"Yangfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Epidemiology, Peking University Clinical Research Institute, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":false,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[{"name":"Endocrinology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2026022606152128000_16.2.e111364.1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.21106","article-title":"Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026022606152128000_16.2.e111364.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.50"},{"key":"2026022606152128000_16.2.e111364.3","article-title":"One-Year Mortality Rates Following Fragility Femoral Fractures in Patients Presenting to King Saud Medical City in Riyadh, Saudi Arabia: A Retrospective Study","volume":"14","author":"ALJohani","year":"2022","journal-title":"Cureus"},{"key":"2026022606152128000_16.2.e111364.4","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s00198-015-3162-6","article-title":"A survey of outcomes and management of patients post fragility fractures in China","volume":"26","author":"Wang","year":"2015","journal-title":"Osteoporos Int"},{"key":"2026022606152128000_16.2.e111364.5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3093-2","article-title":"Projection of osteoporosis-related fractures and costs in China: 2010\u20132050","volume":"26","author":"Si","year":"2015","journal-title":"Osteoporos Int"},{"key":"2026022606152128000_16.2.e111364.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3868-0"},{"key":"2026022606152128000_16.2.e111364.7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eprac.2021.01.019","article-title":"AACE\/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update: Risk Stratification and Intervention Thresholds","volume":"27","author":"Chandran","year":"2021","journal-title":"Endocr Pract"},{"key":"2026022606152128000_16.2.e111364.8","first-page":"26","article-title":"Osteoporosis therapy - Update 2025, Part 1: Antiresorptive and osteoanabolic therapy options","volume":"82","author":"Ferrari","year":"2025","journal-title":"Ther Umsch"},{"key":"2026022606152128000_16.2.e111364.9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022606152128000_16.2.e111364.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.108"},{"key":"2026022606152128000_16.2.e111364.11","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s00198-024-07208-z","article-title":"Real-world efficacy of a teriparatide biosimilar (RGB-10) compared with reference teriparatide on bone mineral density, trabecular bone score, and bone parameters assessed using quantitative ultrasound, 3D-SHAPER\u00ae and high-resolution peripheral computer tomography in postmenopausal women with osteoporosis and very high fracture risk","volume":"35","author":"Hadji","year":"2024","journal-title":"Osteoporos Int"},{"key":"2026022606152128000_16.2.e111364.12","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S181929"},{"key":"2026022606152128000_16.2.e111364.13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00774-024-01536-0","article-title":"Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis","volume":"43","author":"Ebina","year":"2025","journal-title":"J Bone Miner Metab"},{"key":"2026022606152128000_16.2.e111364.14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eprac.2024.10.017","article-title":"Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis","volume":"31","author":"Tabatabai","year":"2025","journal-title":"Endocr Pract"},{"key":"2026022606152128000_16.2.e111364.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"2026022606152128000_16.2.e111364.16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4175"},{"key":"2026022606152128000_16.2.e111364.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.04.007"},{"key":"2026022606152128000_16.2.e111364.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61120-5"},{"key":"2026022606152128000_16.2.e111364.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050336"},{"key":"2026022606152128000_16.2.e111364.20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1055\/a-1062-9447","article-title":"Adherence to Teriparatide Treatment and Risk of Fracture: A Systematic Review and Meta-Analysis","volume":"51","author":"Chen","year":"2019","journal-title":"Horm Metab Res"},{"key":"2026022606152128000_16.2.e111364.21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00198-014-2971-3","article-title":"Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis","volume":"26","author":"Bonafede","year":"2015","journal-title":"Osteoporos Int"},{"key":"2026022606152128000_16.2.e111364.22","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/654218","article-title":"Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study","volume":"2013","author":"Tanaka","year":"2013","journal-title":"J Osteoporos"},{"key":"2026022606152128000_16.2.e111364.23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jbspin.2018.01.005","article-title":"Teriparatide persistence and tolerance in patients with osteoporosis: Observational data from clinical practice","volume":"85","author":"Taisne","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2026022606152128000_16.2.e111364.24","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-017-0316-5","article-title":"Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States","volume":"12","author":"Durden","year":"2017","journal-title":"Arch Osteoporos"},{"key":"2026022606152128000_16.2.e111364.25","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00198-022-06495-8","article-title":"Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk","volume":"33","author":"Shin","year":"2022","journal-title":"Osteoporos Int"},{"key":"2026022606152128000_16.2.e111364.26","article-title":"Effects of Teriparatide Treatment on Bone Mineral Density in Patients With Osteoporosis: A Short-Term Dose-Response Study","volume":"15","author":"Roy","year":"2023","journal-title":"Cureus"},{"key":"2026022606152128000_16.2.e111364.27","first-page":"506","article-title":"SPIRIT 2013 Statement: defining standard protocol items for clinical trials","volume":"38","author":"Chan","year":"2015","journal-title":"Rev Panam Salud Publica"},{"key":"2026022606152128000_16.2.e111364.28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4440"},{"key":"2026022606152128000_16.2.e111364.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60856-9"},{"key":"2026022606152128000_16.2.e111364.30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CP201632","article-title":"Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database","volume":"50","author":"Ziller","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2026022606152128000_16.2.e111364.31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00198-011-1843-3","article-title":"The impact of teriparatide adherence and persistence on fracture outcomes","volume":"23","author":"Yu","year":"2012","journal-title":"Osteoporos Int"},{"key":"2026022606152128000_16.2.e111364.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06626-1"},{"key":"2026022606152128000_16.2.e111364.33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2026022606152128000_16.2.e111364.34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00223-018-0437-x","article-title":"Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo\u00ae Observational Study (ExFOS)","volume":"103","author":"Napoli","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"2026022606152128000_16.2.e111364.35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/clinem\/dgad496","article-title":"Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis","volume":"109","author":"Ramchand","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026022606152128000_16.2.e111364.36","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","article-title":"A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05","volume":"32","author":"Hagino","year":"2021","journal-title":"Osteoporos Int"},{"key":"2026022606152128000_16.2.e111364.37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00198-017-4286-7","article-title":"Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur","volume":"29","author":"Greenspan","year":"2018","journal-title":"Osteoporos Int"},{"key":"2026022606152128000_16.2.e111364.38","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X09339551"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-111364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:15:33Z","timestamp":1772115333000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-111364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,26]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-111364"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-111364","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}